NEW YORK, May 16 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB) has announced details of the methodology and purpose of its Phase I Human Trials with its PulmoBind Molecular Imaging technology for the diagnosis of Pulmonary Embolism and Pulmonary Hypertension.
The work will be carried out by the Pulmo BioTech subsidiary, PulmoScience Inc., and the title of the work is: "Phase I Study of the Use of PulmoBind for Molecular Imaging of the Pulmonary Circulation."
The study will be a single center, Phase 1 safety and efficacy study of
a single intravenous injection of PulmoBind in human subjects with no
history of lung disease.
The Outcomes will be:
1. Safety -- to determine pharmacokinetics and biodistribution of
PulmoBind in humans and to perform dosimetric evaluation
2. Efficacy -- to evaluate the ability of PulmoBind to allow lung
perfusion imaging in humans
Pulmo BioTech expects this work to be completed by late summer 2008.
About Pulmo BioTech Inc.
Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Pulmo BioTech's mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.
About PulmoScience Inc.
PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind.
The company was conceived within the Montreal Heart Institute "MHI" (a
world renowned h
|SOURCE Pulmo BioTech Inc.|
Copyright©2008 PR Newswire.
All rights reserved